NASDAQ:VSTM

Verastem (VSTM) Stock Price, News & Analysis

$9.74
-0.10 (-1.02%)
(As of 04/22/2024 ET)
Today's Range
$9.67
$10.00
50-Day Range
$9.74
$13.12
52-Week Range
$4.26
$15.18
Volume
95,499 shs
Average Volume
139,322 shs
Market Capitalization
$246.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.79

Verastem MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
195.5% Upside
$28.79 Price Target
Short Interest
Healthy
3.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.42mentions of Verastem in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$6,619 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.31) to ($2.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.59 out of 5 stars

Medical Sector

433rd out of 910 stocks

Pharmaceutical Preparations Industry

197th out of 426 stocks

VSTM stock logo

About Verastem Stock (NASDAQ:VSTM)

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

VSTM Stock Price History

VSTM Stock News Headlines

Verastem, Inc. (VSTM)
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Verastem, Inc. (NASDAQ:VSTM) Short Interest Down 17.9% in March
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
VSTM Apr 2024 11.000 call
VSTM Apr 2024 14.000 call
Recap: Verastem Q4 Earnings
VSTM Stock Earnings: Verastem Misses EPS for Q4 2023
VSTM Mar 2024 2.000 put
See More Headlines
Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/22/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VSTM
CUSIP
92337C10
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.79
High Stock Price Target
$36.00
Low Stock Price Target
$17.50
Potential Upside/Downside
+195.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-87,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.60 million
Book Value
$2.27 per share

Miscellaneous

Free Float
24,751,000
Market Cap
$246.27 million
Optionable
Optionable
Beta
0.48
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Daniel W. Paterson (Age 63)
    President, CEO & Director
    Comp: $697.98k
  • Mr. Daniel Calkins (Age 36)
    CFO and Principal Accounting & Financial Officer
    Comp: $1.42M
  • Mr. Richard H. Aldrich M.B.A. (Age 70)
    Founder and Consultant
    Comp: $38.39k
  • Dr. Robert A. Weinberg Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta Ph.D.
    Co-Founder
  • Dr. Michelle Dipp M.D. (Age 48)
    Ph.D., Co-Founder
  • Mr. Robert Pintar M.B.A.
    Senior Vice President of Technical Operations
  • Dr. Jonathan Pachter Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $238.18k
  • Mr. Nate Sanburn
    Senior Vice President of Corporate Development & External Engagement
  • Dr. Hagop Youssoufian M.D. (Age 67)
    M.Sc., Ph.D., Head of Medical Strategy

VSTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Verastem stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings
or view top-rated stocks.

What is Verastem's stock price target for 2024?

7 equities research analysts have issued 12-month price targets for Verastem's stock. Their VSTM share price targets range from $17.50 to $36.00. On average, they anticipate the company's share price to reach $28.79 in the next year. This suggests a possible upside of 195.5% from the stock's current price.
View analysts price targets for VSTM
or view top-rated stocks among Wall Street analysts.

How have VSTM shares performed in 2024?

Verastem's stock was trading at $8.14 at the start of the year. Since then, VSTM stock has increased by 19.7% and is now trading at $9.74.
View the best growth stocks for 2024 here
.

Are investors shorting Verastem?

Verastem saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 634,500 shares, a decrease of 17.9% from the March 15th total of 773,100 shares. Based on an average daily trading volume, of 148,900 shares, the short-interest ratio is presently 4.3 days. Approximately 3.1% of the company's stock are sold short.
View Verastem's Short Interest
.

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VSTM earnings forecast
.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) issued its quarterly earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.20.

When did Verastem's stock split?

Verastem's stock reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

Who are Verastem's major shareholders?

Verastem's stock is owned by many different retail and institutional investors. Top institutional investors include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon.
View institutional ownership trends
.

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VSTM) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners